V
Vivian Fonseca
Researcher at Tulane University
Publications - 133
Citations - 12058
Vivian Fonseca is an academic researcher from Tulane University. The author has contributed to research in topics: Diabetes mellitus & Type 2 diabetes. The author has an hindex of 41, co-authored 133 publications receiving 11230 citations. Previous affiliations of Vivian Fonseca include University College London & University of Massachusetts Medical School.
Papers
More filters
Journal ArticleDOI
The Metabolic Syndrome and Chronic Kidney Disease in U.S. Adults
Jing Chen,Paul Muntner,L Lee Hamm,Daniel W. Jones,Vecihi Batuman,Vivian Fonseca,Paul K. Whelton,Jiang He +7 more
TL;DR: The association between the metabolic syndrome and risk for chronic kidney disease and microalbuminuria in a large representative sample of U.S. adults who participated in the NHANES III was examined.
Journal ArticleDOI
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus A scientific statement from the American Heart Association and the American Diabetes Association
John B. Buse,Henry N. Ginsberg,George L. Bakris,Nathaniel G. Clark,Fernando Costa,Robert H. Eckel,Vivian Fonseca,Hertzel C. Gerstein,Scott M. Grundy,Richard W. Nesto,Michael Pignone,Jorge Plutzky,Daniel Porte,Rita F. Redberg,Kimberly F. Stitzel,Neil J. Stone +15 more
TL;DR: This statement will attempt to harmonize the recommendations of both organizations where possible but will recognize areas in which AHA and ADA recommendations differ.
Journal ArticleDOI
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure A Consensus Statement From the American Heart Association and American Diabetes Association
Richard W. Nesto,David S.H. Bell,Robert O. Bonow,Vivian Fonseca,Scott M. Grundy,Edward S. Horton,Martin Le Winter,Daniel Porte,Clay F. Semenkovich,Sidney C. Smith,Lawrence H. Young,Richard Kahn +11 more
TL;DR: Because people with diabetes are at increased risk for CVD and many have preexisting heart disease, the edema that sometimes accompanies the use of a TZD can be cause for concern, as it may be a harbinger or sign of congestive heart failure (CHF).
Journal ArticleDOI
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus A Scientific Statement From the American Heart Association and the American Diabetes Association
John B. Buse,Henry N. Ginsberg,George L. Bakris,Nathaniel G. Clark,Fernando Costa,Robert H. Eckel,Vivian Fonseca,Hertzel C. Gerstein,Scott M. Grundy,Richard W. Nesto,Michael Pignone,Jorge Plutzky,Daniel Porte,Rita F. Redberg,Kimberly F. Stitzel,Neil J. Stone +15 more
TL;DR: This statement will attempt to harmonize the recommendations of both organizations where possible but will recognize areas in which AHA and ADA recommendations differ.
Journal ArticleDOI
Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.
George L. Bakris,George L. Bakris,George L. Bakris,Vivian Fonseca,Vivian Fonseca,Richard E. Katholi,Richard E. Katholi,Janet B. McGill,Franz H. Messerli,Franz H. Messerli,Franz H. Messerli,Robert A. Phillips,Philip Raskin,Jackson T. Wright,Rosemary Oakes,Mary Ann Lukas,Karen M. Anderson,David S.H. Bell,David S.H. Bell +18 more
TL;DR: Use of carvedilol in the presence of RAS blockade did not affect glycemic control and improved some components of the metabolic syndrome relative to metoprolol in participants with DM and hypertension.